logo
Philadelphia nonprofit has concerns about Trump administration's plan to dismantle CDC's HIV prevention division

Philadelphia nonprofit has concerns about Trump administration's plan to dismantle CDC's HIV prevention division

CBS News29-03-2025

Philadelphia's Mazzoni Center is one of more than a dozen LGBTQ+ health organizations against President Trump's plans to potentially
defund critical HIV prevention initiatives
.
The Trump administration is reportedly considering dismantling the Centers for Disease Control and Prevention's division dedicated to HIV prevention, a move that could shift its responsibilities to another department within the U.S. Department of Health and Human Services.
This potential restructuring has drawn strong condemnation from health organizations across the country, particularly those in the LGBTQ+ and HIV communities, who fear it could jeopardize years of progress in the fight against HIV/AIDS.
David Fair is a long-time HIV/AIDS advocate in Philadelphia and played a key role in the city's early response to the epidemic.
Fair, who co-founded organizations such as the Philadelphia Lesbian and Gay Task Force and Lavender Health (now known as the Mazzoni Center), warns that dismantling the CDC's HIV programs would undo decades of work and could result in a resurgence of new infections and unnecessary deaths.
"If the president gets what he's looking to do, we're going to have more people dying from AIDS," said Fair. "I believe at a rate that we haven't seen for years and years and years because there simply won't be the infrastructure."
Fair's involvement with the HIV/AIDS crisis dates back to the 1980s, when the disease was still largely misunderstood and stigmatised, and its effects were devastating the gay community.
"We called it the gay cancer," Fair recalls, remembering how those diagnosed with HIV often faced death within a few months. At the time, there were few treatment options, and the response from public health officials was slow and reluctant.
Despite the overwhelming challenge, Fair and others in Philadelphia worked to create a robust system of care for people living with HIV, including specialized programs for those dealing with mental illness, drug addiction, and other vulnerabilities.
"We didn't just take a public health approach; we took a comprehensive approach," Fair said. This approach, which focused on addressing the complex needs of people with HIV, has continued to shape the city's HIV care system to this day.
Fair's personal connection to the epidemic has only grown stronger over the years. He recently lost his husband, Rudy, to kidney disease complicated by HIV, a painful reminder of the ongoing struggles of people living with the virus.
One organization that could be significantly impacted by changes to federal HIV funding is the Mazzoni Center, serving the LGBTQ+ community and others for 45 years. With an estimated 18,000 people living with HIV in Philadelphia, the Mazzoni Center plays a pivotal role in providing HIV care, treatment, prevention and education.
Dr. Stacey Trooskin, the Chief Medical Officer at Mazzoni, expressed deep concern about the potential loss of federal funding.
"HIV prevention dollars make all of the programmatic work possible," Trooskin said. "Without those dollars, we'll be at a true disadvantage."
She added that many of their patients are already worried about losing access to crucial HIV medications, such as PrEP (pre-exposure prophylaxis), as well as treatment options for those already living with HIV.
"There are many patients coming in right now who are scared," Trooskin explained. "They're scared they won't have access to their HIV medications, and they won't have access to the support they need to stay healthy."

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

BioNTech to Acquire CureVac in Stock Deal Valued Around $1.25 Billion
BioNTech to Acquire CureVac in Stock Deal Valued Around $1.25 Billion

Yahoo

time16 minutes ago

  • Yahoo

BioNTech to Acquire CureVac in Stock Deal Valued Around $1.25 Billion

BioNTech will acquire all shares of CureVac after the two sides reached an agreement in a deal valued around $1.25 billion. Each share of CureVac, a clinical-stage biotech company, will be exchanged for about $5.46 in BioNTech American depositary shares. Upon the deal's closing, CureVac shareholders are expected to own between 4% and 6% of the German developer of RNA vaccines and immunotherapies. ICE Raids Have Sent Latino Shoppers Into Hiding and Big Brands Are Hurting The Secret to Retaining the Best Employees: Ask Them These Four Questions Here's How Much Money the U.S. Is Earning From Tariffs, in Charts How Home Depot Became Ground Zero in Trump's Deportation Push Supply Chains Become New Battleground in the Global Trade War BioNTech Chief Executive Ugur Sahin said the plan is to bring complementary capabilities between the two companies together to develop transformative cancer treatments. CureVac's operating subsidiary will become a wholly owned subsidiary of BioNTech following the close of the transaction. As part of this plan, BioNTech will integrate CureVac's research and manufacturing site in Tübingen, Germany. The deal was unanimously approved by both companies' management and supervisory boards. It is expected to close in 2025. Shares of CureVac surged 29% to $5.25 in premarket trading. Write to Denny Jacob at Pulls Outlook as Sales Fall Bojangles Is Exploring a Sale While the Fried-Chicken Market Is Hot Why Bosses Should Give Feedback in the Morning The Audacious Reboot of America's Nuclear Energy Program Muted May Inflation Defies Tariff Fears Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Opinion: It's Time to Buy UnitedHealth Group Stock After a 50% Plunge
Opinion: It's Time to Buy UnitedHealth Group Stock After a 50% Plunge

Yahoo

time17 minutes ago

  • Yahoo

Opinion: It's Time to Buy UnitedHealth Group Stock After a 50% Plunge

Most of UnitedHealth Group's issues should be temporary. The two biggest threats to the healthcare giant are iffy. The price is right to buy UnitedHealth Group stock after its steep decline. 10 stocks we like better than UnitedHealth Group › UnitedHealth Group (NYSE: UNH) might want to change its stock ticker from "UNH" to "UGH." The latter better captures the feelings of the healthcare giant's shareholders in recent months. A string of problems has caused UnitedHealth Group's share price to plunge roughly 50% from the peak set in the fourth quarter of 2024. Some analysts have downgraded the stock, with HSBC recommending that investors reduce their holdings and slashing its price target. I have a different opinion, though. I think it's time to buy UnitedHealth Group stock. Here are three reasons why. I don't think investors should ignore UnitedHealth Group's issues. However, the challenges should be viewed with a long-term perspective. I suspect most of the problems the company faces should be temporary. UnitedHealth Group has already largely moved past the cyberattack that occurred in February 2024. Although it cost the healthcare company over $2 billion, that issue has already proven to be a short-lived one. Higher Medicare Advantage costs are the main culprit behind UnitedHealth Group's suspension of its 2025 full-year guidance. But the company says that it expects to return to growth in 2026. I believe this prediction because it makes sense. Insurers sometimes incur higher-than-anticipated costs and feel the pain for a while. However, once they adjust premiums, the problem goes away. UnitedHealth Group announced the sudden departure of former CEO Andrew Witty at the same time it withdrew its 2025 outlook. Any worries investors might have had surrounding this move probably dissipated quickly after they learned Stephen Hemsley was returning to run the company. Hemsley served as CEO from 2006 through 2017, a period when UnitedHealth Group stock more than tripled. I also view the two biggest threats to UnitedHealth Group as iffy. What are those threats? An alleged U.S. Department of Justice criminal investigation of the company and President Trump's stated goal to eliminate pharmacy benefits managers (PBMs). Noted that I used the word "alleged" to describe the U.S. Department of Justice probe. The Wall Street Journal reported on May 14, 2025, that "people familiar with the matter" revealed that the DOJ had launched a criminal investigation of UnitedHealth Group for possible Medicare fraud. However, the company quickly responded that it hadn't been notified of any DOJ investigation. That status hasn't changed. President Trump did announce that he wants to "cut out the middleman," a clear reference to PBMs. That's easier said than done, though, to put it mildly. Removing PBMs from the U.S. healthcare system would require a detailed, comprehensive plan that so far has not been provided. That plan would also have to pass in both the Senate and the House of Representatives. You can bet that the PBM industry, including UnitedHealth Group, would lobby fiercely against any such legislation. I think this threat, while serious, has a relatively low probability of actually materializing. Finally, I think all these issues are fully baked into UnitedHealth Group's share price. The stock currently trades at a forward price-to-earnings ratio of around 13.3. That's well below the S&P 500 healthcare sector forward earnings multiple of 16.6. It's also the lowest valuation for UnitedHealth Group in more than a decade. Could the stock fall further? Maybe, but I believe that UnitedHealth Group's share price has bottomed out. You might have noticed that UnitedHealth Group's share price has traded in a relatively narrow range since the steep decline in April and May. This trading pattern seems to confirm my view. Any good news for UnitedHealth Group could provide a nice catalyst. I predict that the company will have some positive developments in the not-too-distant future, potentially including new full-year guidance that calms investors. If I'm right, buying UnitedHealth Group stock now could pay off handsomely. Before you buy stock in UnitedHealth Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $649,102!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $882,344!* Now, it's worth noting Stock Advisor's total average return is 996% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 HSBC Holdings is an advertising partner of Motley Fool Money. Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends HSBC Holdings and UnitedHealth Group. The Motley Fool has a disclosure policy. Opinion: It's Time to Buy UnitedHealth Group Stock After a 50% Plunge was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

RFK Jr. announces eight new members of vaccine panel after firing all 17 members
RFK Jr. announces eight new members of vaccine panel after firing all 17 members

Yahoo

time32 minutes ago

  • Yahoo

RFK Jr. announces eight new members of vaccine panel after firing all 17 members

Two days after he fired all 17 members of a committee that advises the federal government on vaccine safety, Health Secretary Robert F. Kennedy, Jr. announced eight new members, including a physician criticized for spreading COVID-19 misinformation and conspiracy theories. Vaccine experts warned Kennedy's abrupt termination of the entire committee on June 9 would create public distrust around the government's role in promoting public health. The new list of members includes scientists, public-health experts and physicians. "All of these individuals are committed to evidence-based medicine, gold-standard science, and common sense," wrote Kennedy in a post on X on June 11. "They have each committed to demanding definitive safety and efficacy data before making any new vaccine recommendations." The Advisory Committee for Immunization Practices makes recommendations on the safety, efficacy and clinical need of vaccines to the Centers for Disease Control and Prevention. It comprises medical and public health experts who develop recommendations on the use of vaccines in the civilian population of the United States. "The committee will review safety and efficacy data for the current schedule as well," noted Kennedy, who has a history of controversial views on vaccines. Dr. Paul A. Offit, director of the Vaccine Education Center at Children's Hospital of Philadelphia and a member of the Food and Drug Administration Vaccines and Related Biological Products Advisory Committee, previously told USA TODAY that Kennedy was "fixing a problem that doesn't exist," by overhauling the committee. Picking members for the committee generally involves a three- to four-month vetting process by the CDC. Offit said he would "presumably pick people who are like-minded, and I think that will shake confidence in this committee." Kennedy's list of picks includes some widely-respected experts, such as Dr. Cody Meissner, chief of pediatric infectious diseases at Tufts Children's Hospital. However, it also includes some prominent figures who have criticized vaccines. One of them, Dr. Robert Malone, is a virologist and vaccine skeptic who became well-known during the COVID-19 pandemic for spreading misinformation about the virus on conservative shows and podcasts. His appearance on 'The Joe Rogan Experience' prompted public uproar against Spotify after Malone promoted false and misleading conspiracy theories about the vaccine, even invoking Nazi Germany. The physician-scientist and biochemist has falsely claimed spike proteins from COVID-19 mRNA vaccines often cause permanent damage to children's vital organs. Kennedy's picks for ACIP also includes Vicky Pebsworth, ⁠who has been listed on the board of the National Vaccine Information, a group widely criticized for spreading vaccine misinformation. Retsef Levi, a professor of operations management at the MIT Sloan School of Management, was also picked to serve on the federal advisory committee. In 2023, ⁠he posted a video on X criticizing COVID-19 vaccines. The post is pinned to his profile. 'The evidence is mounting and indisputable that MRNA vaccines cause serious harm including death, especially among young people,' he said. 'We have to stop giving them immediately!' Dr. Martin Kulldorff, another one of Kennedy's ACIP picks, wrote ⁠a paper published in the Journal of the Academy of Public Health in March that called for a 'COVID Commission' that would investigate the National Institutes of Health's handling of the pandemic. Other appointees include: Dr. Joseph R. Hibbeln, a psychiatrist and neuroscientist with a career in clinical research, public health policy, and federal service; Dr. James Pagano, an emergency medicine physician; Michael A. Ross, a clinical professor of Obstetrics and Gynecology at George Washington University and Virginia Commonwealth University. This article originally appeared on USA TODAY: RFK Jr. bring on eight members on vaccine panel

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store